IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors

PURPOSE: Somatic mutations in IDH1/2 occur in ~20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2(MUT) enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increases in DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in so...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Molenaar, Remco J., Radivoyevitch, Tomas, Nagata, Yasunobu, Khurshed, Mohammed, Przychodzen, Bartolomiej, Makishima, Hideki, Xu, Mingjiang, Bleeker, Fonnet E., Wilmink, Johanna W., Carraway, Hetty E., Mukherjee, Sudipto, Sekeres, Mikkael A., van Noorden, Cornelis J.F., Maciejewski, Jaroslaw P.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884732/
https://ncbi.nlm.nih.gov/pubmed/29339439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2796
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料